Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Predicting 15-year prostate cancer specific mortality after radical prostatectomy.
Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW, Yu C, Klein EA, Stephenson AJ.
J Urol. 2011 Mar;185(3):869-75. doi: 10.1016/j.juro.2010.10.057. Epub 2011 Jan 15.
Similar articles
Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality.
Stephenson AJ, Eggener SE, Hernandez AV, Klein EA, Kattan MW, Wood DP Jr, Rabah DM, Eastham JA, Scardino PT.
Eur Urol. 2014 Apr;65(4):675-80. doi: 10.1016/j.eururo.2013.08.036. Epub 2013 Aug 27.
Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy.
Yossepowitch O, Eggener SE, Serio AM, Carver BS, Bianco FJ Jr, Scardino PT, Eastham JA.
Eur Urol. 2008 May;53(5):950-9. Epub 2007 Oct 12.
The natural history of noncastrate metastatic prostate cancer after radical prostatectomy.
Yossepowitch O, Bianco FJ Jr, Eggener SE, Eastham JA, Scher HI, Scardino PT.
Eur Urol. 2007 Apr;51(4):940-7; discussion 947-8. Epub 2006 Oct 30.
Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
Yossepowitch O, Eggener SE, Bianco FJ Jr, Carver BS, Serio A, Scardino PT, Eastham JA.
J Urol. 2007 Aug;178(2):493-9; discussion 499. Epub 2007 Jun 11.
Radical prostatectomy shortly after prostate biopsy does not affect operative difficulty or efficacy.
Eggener SE, Yossepowitch O, Serio AM, Vickers AJ, Scardino PT, Eastham JA.
Urology. 2007 Jun;69(6):1128-33.
Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.
Eggener SE, Roehl KA, Smith ND, Antenor JA, Han M, Catalona WJ.
J Urol. 2005 Apr;173(4):1150-5.
A multi-institutional evaluation of active surveillance for low risk prostate cancer.
Eggener SE, Mueller A, Berglund RK, Ayyathurai R, Soloway C, Soloway MS, Abouassaly R, Klein EA, Jones SJ, Zappavigna C, Goldenberg L, Scardino PT, Eastham JA, Guillonneau B.
J Urol. 2009 Apr;181(4):1635-41; discussion 1641. doi: 10.1016/j.juro.2008.11.109. Epub 2009 Feb 23.
Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies.
Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ.
J Urol. 2004 Dec;172(6 Pt 1):2227-31.
Focal therapy for prostate cancer: possibilities and limitations.
Eggener S, Salomon G, Scardino PT, De la Rosette J, Polascik TJ, Brewster S.
Eur Urol. 2010 Jul;58(1):57-64. doi: 10.1016/j.eururo.2010.03.034. Epub 2010 Mar 26. Review. Erratum in: Eur Urol. 2010 Oct;58(4):644.
Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
Eggener SE, Roehl KA, Yossepowitch O, Catalona WJ.
J Urol. 2006 Oct;176(4 Pt 1):1399-403.
J Urol. 2013 Jan;189(1 Suppl):S19-25; discussion S25. doi: 10.1016/j.juro.2012.11.023.
Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program.
Eggener SE, Yossepowitch O, Roehl KA, Loeb S, Yu X, Catalona WJ.
Urology. 2008 Jun;71(6):1016-9. doi: 10.1016/j.urology.2007.12.008. Epub 2008 Mar 21.
Comparison of models to predict clinical failure after radical prostatectomy.
Eggener SE, Vickers AJ, Serio AM, Donovan MJ, Khan FM, Bayer-Zubek V, Verbel D, Cordon-Cardo C, Reuter VE, Bianco FJ Jr, Scardino PT.
Cancer. 2009 Jan 15;115(2):303-10. doi: 10.1002/cncr.24016.
Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance.
Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BD.
J Urol. 2008 Nov;180(5):1964-7; discussion 1967-8. doi: 10.1016/j.juro.2008.07.051. Epub 2008 Sep 17.
Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma.
Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P.
J Urol. 2008 Sep;180(3):873-8; discussion 878. doi: 10.1016/j.juro.2008.05.006. Epub 2008 Jul 17.
Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease.
Antenor JA, Roehl KA, Eggener SE, Kundu SD, Han M, Catalona WJ.
Urology. 2005 Jul;66(1):156-60.
Hazard of prostate cancer specific mortality after radical prostatectomy.
Shikanov S, Eggener SE.
J Urol. 2012 Jan;187(1):124-7. doi: 10.1016/j.juro.2011.09.044. Epub 2011 Nov 23.
Positive surgical margins at partial nephrectomy: predictors and oncological outcomes.
Yossepowitch O, Thompson RH, Leibovich BC, Eggener SE, Pettus JA, Kwon ED, Herr HW, Blute ML, Russo P.
J Urol. 2008 Jun;179(6):2158-63. doi: 10.1016/j.juro.2008.01.100.
Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy.
Bjartell AS, Al-Ahmadie H, Serio AM, Eastham JA, Eggener SE, Fine SW, Udby L, Gerald WL, Vickers AJ, Lilja H, Reuter VE, Scardino PT.
Clin Cancer Res. 2007 Jul 15;13(14):4130-8.
Filters: Manage Filters